Hisamitsu Pharmaceutical Co., Ltd. (Headquarters: Tosu City, Saga Prefecture, President and Chief Executive Officer (CEO): Hirotaka Nakatomi (hereinafter “Hisamitsu Pharmaceutical”), in conjunction with its U.S. subsidiary, Noven Pharmaceuticals, Inc. (hereinafter “Noven Pharmaceuticals”) announces that the transdermal patch for the treatment of schizophrenia (Development code: HP-3070, generic name: asenapine maleate, hereinafter referred to as “the investigational product”) achieved the primary endpoint of the Phase III clinical trial in the U.S.
3 Likes
There is a transdermal patch for abilify in the works too.
More up to date progress in this link:
https://scienceinthecity.com/2017/08/31/development-path-transdermal-aripiprazole/
2 Likes